Citations

Clear

4847 citation(s) found for "Yu, Eric".

Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes
O’Malley, Grenye , Raghinaru, Dan, Kudva, Yogish C. , Laffel, Lori M. , Pinsker, Jordan E. , Lum, John W. , Brown, Sue A. , Anderson, Stacey M. , Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David W. , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Forlenza, Gregory P. , Slover, Robert H., Jost, Emily , Berget, Cari , Towers, Lindsey, Rossick-Solis, Alex, Ekhlaspour, Laya , Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Kollman, Craig, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Eggerman, Thomas L., Green, Neal, Reznik, Yves , Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Kudva, Yogish C. , Laffel, Lori M , Pinsker, Jordan E , Lum, John , Forlenza, Gregory P , Levy, Carol J. , Kovatchev, Boris , Oliveri, Mary Clancy , Isganaitis, Elvira , Kumari, Kanchan, Wadwa, R Paul , Alonso, G. Todd , Messer, Laurel H , Buckingham, Bruce A. , Doyle, Francis J. , Beck, Roy W. , Kollman, Craig , Renard, Eric , Cobelli, Claudio , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | January 31, 2022 | Volume: 24 | Issue: 5 | Pages: 357-361

10.1089/dia.2021.0431 | PMID 35099294 Get It

Objective: To analyze insulin delivery and glycemic metrics throughout the menstrual cycle for women with type 1 diabetes using closed loop control (CLC) insulin delivery. Methods: Menstruating women using a CLC system in a clinical trial were invited to record their menstrual cycles through a cycle-tracking application. Sixteen participants provided data for this secondary analysis over three or more complete cycles. Insulin delivery and continuous glucose monitoring (CGM) data were analyzed in relation to reported cycle phases. Results: Insulin delivery and CGM metrics remained consistent during cycle phases. Intraparticipant variability of CGM metrics and weight-based insulin delivery did not change through cycle phases. Conclusions: For this sample of menstruating women with type 1 diabetes using a CLC system, insulin delivery and glycemic metrics remained stable throughout menstrual cycle phases. Additional studies in this population are needed, particularly among women who report variable glycemic control during their cycles. Trial Registration: NCT03591354.
Meeting Report: Aging Research and Drug Discovery
Meron, Esther, Thaysen, Maria, Antebi, Adam , Barzilai, Nir , Birkisdóttir, María B. , Bruening, Jens, Brunet, Anne , Cai, Shi‐Qing , Chen, Brian H. , Ermolaeva, Maria , Ewald, Collin Y. , Ferrucci, Luigi , Fortney, Kristen , Freund, Adam , Georgievskaya, Anastasia , Gladyshev, Vadim N. , Golato, Tyler, Hoejimakers, Jan, Houtkooper, Riekelt H. , Jaksch, Frank, Janssens, Georges E. , Jensen, Martin Borch , Kirkland, James L. , Kjær, Michael , Lee, Kai-Fu, Lemaı̂tre, Jean-Marc , Liaskos, David, Longo, Valter D. , Lu, Yuxuan , MacArthur, Michael R. , Maier, Andrea B. , Manakanatas, Christina, Mitchell, Sarah J. , Moskalev, Alexey , Niedernhofer, Laura J. , Ozerov, Ivan V. , Peyer, James , Radenković, Dina , Rattan, Suresh I. S. , Riedel, Christian G. , Schumacher, Björn , Smith, Ryan , Suh, Yousin , Trapp, Alexandre , Trendelenburg, Anne‐Ulrike, Valenzano, Dario Riccardo , Verburgh, Kris, Zhavoronkov, Alex , Niedernhofer, Laura J , Ferrucci, Luigi , Gladyshev, Vadim N , Thaysen, Maria , Angeli, Suzanne , Baur, Joseph A. , Bekker‐Jensen, Simon , Bischof, Evelyne Y. , Bruening, Jens, Buchwalter, Abigail L. , Cabreiro, Filipe , Florian, Maria Carolina , Glass, David J. , Golato, Tyler, Gorbunova, Vera , Jäger, Sibylle , Kaeberlein, Matt R. , Karsenty, Gérard , Keizer, Peter L.J. de , Kennedy, Brian Keith , Kroemer, Guido , Liaskos, David, Partridge, Linda , Passegue, Emmanuelle A. , Petr, Michael Angelo , Rando, Thomas A. , Rudolph, K. Lenhard , Ai, Ruixue , Serrano, Manuel , Sinclair, David , Suh, Yousin , Taub, Pam R. , Verdin, Eric , Vijg, Jan , Westendorp, Rudi G. J. , Zonari, Alessandra Arcoverde Cavalcanti , Bakula, Daniela , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | January 28, 2022 | Volume: 14 | Issue: 2 | Pages: 530-543

10.18632/aging.203859 Get It

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Alva, Ajjai , Carlo, Maria I. , Choueiri, Toni K. , Costello, Brian A. , Derweesh, Ithaar , Desai, Arpita, Ged, Yasser , Kyriakopoulos, Christos E. , Lara, Primo N. , Lau, Clayton, Lewis, Bryan , Michaelson, M. Dror , Mortazavi, Amir , Nandagopal, Lakshminarayanan , Ponsky, Lee , Ramalingam, Sundhar, Shuch, Brian , Smith, Zachary L. , Sosman, Jeffrey A. , Dwyer, Mary A., Gurski, Lisa A., Motter, Angela D., Anderson, Larry D. , Choueiri, Toni K , Anderson, Larry D , Motzer, Robert J. , Jonasch, Eric W. , Agarwal, Neeraj , Baine, Michael J. , Beckermann, Kathryn E. , George, Saby , Gore, John L. , Haas, Naomi B , Hancock, Steven Lee , Kapur, Payal , Lam, Elaine T. , Madoff, David C. , Manley, Brandon J. , Plimack, Elizabeth R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 28, 2022 | Volume: 20 | Issue: 1 | Pages: 71-90

10.6004/jnccn.2022.0001 | PMID 34991070 Get It

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide management of advanced RCC, the NCCN Kidney Cancer Panel has categorized all systemic kidney cancer therapy regimens as “Preferred,” “Other Recommended Regimens,” or “Useful in Certain Circumstances.” This categorization provides guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include pre-existing comorbidities, nature of the disease, and in some cases consideration of access to agents. This article summarizes surgical and systemic therapy recommendations for patients with relapsed or stage IV RCC.
Preoperative Stereotactic Radiosurgery for Glioblastoma
Lehrer, Eric J. , Sindhu, Kunal K. , Estrada, Rachel Sarabia, Borst, Gerben R. , Sheehan, Jason P. , Quiñones‐Hinojosa, Alfredo , Sindhu, Kunal K , Borst, Gerben R , Ruiz-García, Henry , Nehlsen, Anthony D. , Trifiletti, Daniel M.

Mayo Clinic

Biology | January 26, 2022 | Volume: 11 | Issue: 2 | Pages: 194

10.3390/biology11020194 | PMID 35205059 Get It

Glioblastoma is a devastating primary brain tumor with a median overall survival of approximately 15 months despite the use of optimal modern therapy. While GBM has been studied for decades, modern therapies have allowed for a reduction in treatment-related toxicities, while the prognosis has largely been unchanged. Adjuvant stereotactic radiosurgery (SRS) was previously studied in GBM; however, the results were disappointing. SRS is a highly conformal radiation technique that permits the delivery of high doses of ionizing radiation in 1–5 sessions while largely sparing surrounding healthy tissues. Furthermore, studies have shown that the delivery of ablative doses of ionizing radiation within the central nervous system is associated with enhanced anti-tumor immunity. While SRS is commonly used in the definitive and adjuvant settings for other CNS malignancies, its role in the preoperative setting has become a topic of great interest due to the potential for reduced treatment volumes due to the treatment of an intact tumor, and a lower risk of nodular leptomeningeal disease and radiation necrosis. While early reports of SRS in the adjuvant setting for glioblastoma were disappointing, its role in the preoperative setting and its impact on the anti-tumor adaptive immune response is largely unknown. In this review, we provide an overview of GBM, discuss the potential role of preoperative SRS, and discuss the possible immunogenic effects of this therapy.
Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study
Lehrer, Eric J. , Gurewitz, Jason , Bernstein, Kenneth , Patel, Dev , Niranjan, Ajay , Wei, Zhishuo , Lunsford, L. Dade , Malouff, Timothy D. , Patel, Samir , Bonney, Phillip A. , Hwang, Lindsay , Yu, Cheng , Zada, Gabriel , Mathieu, David , Trudel, Claire, Prasad, Rahul N. , Sharma, Sonam , Fakhoury, Kareem , Rusthoven, Chad G. , Deibert, Christopher P., Picozzi, Piero , Franzini, Andrea , Attuati, Luca , Lee, Cheng‐Chia , Ahluwalia, Manmeet S. , Sheehan, Jason P. , Trifiletti, Daniel M , Mathieu, David , Ahluwalia, Manmeet S , Patel, Dev, Kondziolka, Douglas , Ruiz-García, Henry , Palmer, Joshua D. , Jones, Brianna M. , Yang, Huai‐Che , Trifiletti, Daniel M.

Mayo Clinic

Cancer | January 25, 2022 | Volume: 128 | Issue: 7 | Pages: 1429-1438

10.1002/cncr.34087 | PMID 35077586 Get It

BACKGROUNDPatients with renal cell carcinoma (RCC) brain metastases are frequently treated with immune checkpoint inhibitors (ICIs) and stereotactic radiosurgery (SRS). However, data reporting on the risk of developing radiation necrosis (RN) are limited.METHODSRN rates were compared for concurrent therapy (ICI/SRS administration within 4 weeks of one another) and nonconcurrent therapy with the χ2 test. Univariable logistic regression was used to identify factors associated with developing RN.RESULTSFifty patients (23 concurrent and 27 nonconcurrent) with 395 brain metastases were analyzed. The median follow‐up was 12.1 months; the median age was 65 years. The median margin dose was 20 Gy, and 4% underwent prior whole‐brain radiation therapy (WBRT). The median treated tumor volume was 3.32 cm3 (range, 0.06‐42.38 cm3); the median volume of normal brain tissue receiving a dose of 12 Gy or higher (V12 Gy) was 8.42 cm3 (range, 0.27‐111.22 cm3). Any‐grade RN occurred in 17.4% and 22.2% in the concurrent and nonconcurrent groups, respectively (P = .67). Symptomatic RN occurred in 4.3% and 14.8% in the concurrent and nonconcurrent groups, respectively (P = .23). Increased tumor volume during SRS (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.01‐1.19; P = .04) was associated with developing RN, although V12 Gy (OR, 1.03; 95% CI, 0.99‐1.06; P = .06), concurrent therapy (OR, 0.74; 95% CI, 0.17‐2.30; P = .76), prior WBRT, and ICI agents were not statistically significant.CONCLUSIONSSymptomatic RN occurs in a minority of patients with RCC brain metastases treated with ICI/SRS. The majority of events were grade 1 to 3 and were managed medically. Concurrent ICI/SRS does not appear to increase this risk. Attempts to improve dose conformality (reduce V12) may be the most successful mitigation strategy in single‐fraction SRS.
Recurrence Following Endoscopic Laser Wedge Excision and Triple Medical Therapy for Idiopathic Subglottic Stenosis
Bowen, Andrew J. , Xie, Katherine , O’Byrne, Thomas J., Bayan, Semirra L. , Edell, Eric S. , Vassallo, Robert , Ekbom, Dale C. , Kasperbauer, Jan L. , Bowen, Andrew Jay , Xie, Katherine Z , Vassallo, Robert , Bayan, Semirra

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 25, 2022 | Volume: 167 | Issue: 3 | Pages: 524-530

10.1177/01945998221074684 | PMID 35077239 Get It

ObjectiveWe present the outcomes for patients with idiopathic subglottic stenosis (iSGS) following their first carbon dioxide laser wedge excision (LWE) procedure, additionally examining the effect of compliance with adjuvant medical therapy (triple therapy) after the operation.Study DesignRetrospective chart review.SettingTertiary center.MethodsA retrospective review was performed on 183 patients with iSGS following their first LWE and their compliance to adjuvant medical therapy (inhaled corticosteroid, proton pump inhibitor, trimethoprim‐sulfamethoxazole) following the operation, with all reviewed to December 31, 2020. The primary outcome variable was median time to recurrence (MTR). Patients were stratified by whether the LWE was their first operation (LWE primary or secondary), by compliance to triple therapy, and by compliance with trimethoprim‐sulfamethoxazole. Kaplan‐Meier analysis and Cox proportional hazards were used to evaluate the MTR across the stratifications.ResultsAn overall 113 patients underwent their first LWE, while 70 received the procedure after having undergone 1 to 13 procedures. The MTR between LWE primary and secondary was 4.6 and 2.9 years, respectively. Adjusted Cox proportional hazards comparing these 2 groups revealed the number of prior operations to be a confounding variable. A statistically increased MTR was demonstrated with greater degrees of medical compliance.ConclusionLWE conferred an MTR of 4.1 years in the iSGS cohort. The number of prior procedures preceding LWE behaved as a confounding variable. Patients who were completely or partially compliant to triple therapy appear to demonstrate increased intervals prior to recurrence.
The promise of residential treatment to support functional and vocational recovery for young adults with bipolar disorder
Heredia, Dagoberto , Pease, Eric , Puspitasari, Ajeng J. , Pease, Eric R

Mayo Clinic

Bipolar Disorders | January 24, 2022 | Volume: 24 | Issue: 3 | Pages: 340-342

10.1111/bdi.13177 | PMID 35068028 Get It

Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry
Alvi, Mohammed Ali, Asher, Anthony L., Michalopoulos, Giorgos D., Grills, Inga S., Warnick, Ronald E., McInerney, James, Chiang, Veronica L., Attia, Albert, Timmerman, Robert, Chang, Eric, Kavanagh, Brian D., Andrews, David W., Walter, Kevin, Bydon, Mohamad, Sheehan, Jason P., Warnick, Ronald E. , Alvi, Mohammed Ali , Michalopoulos, Giorgos D. , Alvi, Mohammed Ali , Michalopoulos, Giorgos , Alvi, Mohammed Ali, Asher, Anthony L., Grills, Inga S., Warnick, Ronald E., McInerney, James, Chiang, Veronica L., Attia, Albert, Timmerman, Robert, Chang, Eric, Kavanagh, Brian D., Andrews, David W., Walter, Kevin, Bydon, Mohamad, Sheehan, Jason P.

Mayo Clinic

Journal of Neurosurgery | January 21, 2022 | Volume: 137 | Issue: 4 | Pages: 985-998

10.3171/2021.10.jns211410 | PMID 35171833 Get It

OBJECTIVE Stereotactic radiosurgery (SRS) has been increasingly employed in recent years to treat intracranial metastatic lesions. However, there is still a need for optimization of treatment paradigms to provide better local control and prevent progressive intracranial disease. In the current study, the authors utilized a national collaborative registry to investigate the outcomes of patients with intracranial metastatic disease who underwent SRS and to determine factors associated with lesion treatment response, overall progression, and mortality. METHODS The NeuroPoint Alliance SRS registry was queried for all patients with intracranial metastatic lesions undergoing single- or multifraction SRS at participating institutions between 2016 and 2020. The main outcomes of interest included lesion response (lesion-level analysis), progression using Response Assessment for Neuro-Oncology criteria, and mortality (patient-level analysis). Kaplan-Meier analysis was used to report time to progression and overall survival, and multivariable Cox proportional hazards analysis was used to investigate factors associated with lesion response, progression, and mortality. RESULTS A total of 501 patients (1447 intracranial metastatic lesions) who underwent SRS and had available follow-up were included in the current analyses. The most common primary tumor was lung cancer (49.5%, n = 248), followed by breast (15.4%, n = 77) and melanoma (12.2%, n = 61). Most patients had a single lesion (44.9%, n = 225), 29.3% (n = 147) had 2 or 3 lesions, and 25.7% (n = 129) had > 3 lesions. The mean sum of baseline measurements of the lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) was 35.54 mm (SD 25.94). At follow-up, 671 lesions (46.4%) had a complete response, 631 (43.6%) had a partial response (≥ 30% decrease in longest diameter) or were stable (< 30% decrease but < 20% increase), and 145 (10%) showed progression (> 20% increase in longest diameter). On multivariable Cox proportional hazards analysis, melanoma-associated lesions (HR 0.48, 95% CI 0.34–0.67; p < 0.001) and larger lesion size (HR 0.94, 95% CI 0.93–0.96; p < 0.001) showed lower odds of lesion regression, while a higher biologically effective dose was associated with higher odds (HR 1.001, 95% CI 1.0001–1.00023; p < 0.001). A total of 237 patients (47.3%) had overall progression (local failure or intracranial progressive disease), with a median time to progression of 10.03 months after the index SRS. Factors found to be associated with increased hazards of progression included male sex (HR 1.48, 95% CI 1.108–1.99; p = 0.008), while administration of immunotherapy (before or after SRS) was found to be associated with lower hazards of overall progression (HR 0.62, 95% CI 0.460–0.85; p = 0.003). A total of 121 patients (23.95%) died during the follow-up period, with a median survival of 19.4 months from the time of initial SRS. A higher recursive partitioning analysis score (HR 21.3485, 95% CI 1.53202–3.6285; p < 0.001) was found to be associated with higher hazards of mortality, while single-fraction treatment compared with hypofractionated treatment (HR 0.082, 95% CI 0.011–0.61; p = 0.015), administration of immunotherapy (HR 0.385, 95% CI 0.233–0.64; p < 0.001), and presence of single compared with > 3 lesions (HR 0.427, 95% CI 0.187–0.98; p = 0.044) were found to be associated with lower risk of mortality. CONCLUSIONS The comparability of results between this study and those of previously published clinical trials affirms the value of multicenter databases with real-world data collected without predetermined research purpose.
Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
León, José de , Schoretsanitis, Georgios , Smith, Robert L. , Molden, Espen , Solismaa, Anssi , Seppälä, Niko , Kopeček, Miloslav , Švancer, Patrik , Olmos, I. Cánovas , Ricciardi, Carina , Iglesias-Alonso, Ana , Ruan, Can‐Jun , Wang, Chuanyue , Wang, Gang , Tang, Yi‐lang , Kim, Yong Sik , Kim, Se Hyun , Jung–Cook, Helgi , Nielsen, Jimmi , Verdoux, Hélène , Quilès, Clélia , Cohen, Dan , Schulte, Peter F.J. , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O. , Kaithi, Arun R., Farooq, Saeed , Ng, Chee H. , Bilbily, John , Lana, Fernando , Rădulescu, Flavian Ștefan , Seifritz, Erich , Every‐Palmer, Susanna , Bebawi, Emmanuel , Kelly, Deanna L. , Lazáry, Judit , Torres, Rafael , Yécora, Agustín, Berardis, Domenico De , Adebayo, Richard A. , Fountoulakis, Konstantinos Ν. , Ayub, Muhammad , Silva, Alzira , Bonelli, Raphael M., Crespo‐Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria Rosel , Gründer, Gerhard , Čelofiga, Andreja , Ristić, Dragana Ignjatović , Elkis, Hélio , Siskind, Dan , Masmoudi, R. , Saffian, Shamin Mohd , Buckley, P.F. , Freudenreich, Oliver , Müller, Daniel J. , de Leon, Jose , Olmos, Ismael , Iglesias-Garcia, Celso , Iglesias-Alonso, Ana , Spina, Edoardo , Ruan, Can-Jun , Wang, Chuan-Yue , Tang, Yi-Lang , Lin, Shih-Ku , Lane, Hsien-Yuan , Kim, Yong Sik , Kim, Se Hyun , Rajkumar, Anto P , González-Esquivel, Dinora F , Jung-Cook, Helgi , Baptista, Trino , Rohde, Christopher , Nielsen, Jimmi , Verdoux, Hélène , Quiles, Clelia , Sanz, Emilio J , De Las Cuevas, Carlos , Cohen, Dan , Schulte, Peter F J , Ertuğrul, Aygün , Anıl Yağcıoğlu, A Elif , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O , Kane, John M , Farooq, Saeed , Ng, Chee H , Bilbily, John , Hiemke, Christoph , López-Jaramillo, Carlos , McGrane, Ian , Lana, Fernando , Eap, Chin B , Every-Palmer, Susanna , Bousman, Chad A , Bebawi, Emmanuel , Bhattacharya, Rahul , Kelly, Deanna L , Otsuka, Yuji , Lazary, Judit , Motuca, Mariano , Chan, Sherry K W , Zolezzi, Monica , Ouanes, Sami , De Berardis, Domenico , Grover, Sandeep , Procyshyn, Ric M , Adebayo, Richard A , Kirilochev, Oleg O , Soloviev, Andrey , Fountoulakis, Konstantinos N , Wilkowska, Alina , Cubała, Wiesław J , Ayub, Muhammad , Silva, Alzira , Villagrán-Moreno, José M , Crespo-Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria R , Takeuchi, Hiroyoshi , Tsukahara, Masaru , Gründer, Gerhard , Sagud, Marina , Celofiga, Andreja , Ignjatovic Ristic, Dragana , Ortiz, Bruno B , Elkis, Helio , Pacheco Palha, António J , LLerena, Adrián , Fernandez-Egea, Emilio , Siskind, Dan , Weizman, Abraham , Masmoudi, Rim , Mohd Saffian, Shamin , Leung, Jonathan G , Buckley, Peter F , Marder, Stephen R , Citrome, Leslie , Freudenreich, Oliver , Correll, Christoph Ulrich , Müller, Daniel J , Kopecek, Miloslav , Schoretsanitis, Georgios , García, Celso Iglesias , Rajkumar, Anto P. , González‐Esquivel, Dinora F. , Rohde, Christopher , Sanz, Emílio J. , Cuevas, Carlos De las , Yağcıoğlu, A. Elif Anıl , Kane, John M. , Hiemke, Christoph , López‐Jaramillo, Carlos , McGrane, Ian R. , Arrojo, Manuel , Bousman, Chad , Bhattacharya, Rahul , Motuca, Mariano , Chan, Sherry Kit Wa , Кирилочев, О.О. , Soloviev, A. G. , Wilkowska, Alina , Cubała, Wiesław Jerzy , Tsukahara, Masaru , Ortiz, Bruno Bertolucci , LLerena, Adrián , Leung, Jonathan G. , Citrome, Leslie

Mayo Clinic

Pharmacopsychiatry | January 20, 2022 | Volume: 55 | Issue: 02 | Pages: e1-e1

10.1055/a-1737-1527 | PMID 35052001 Get It

Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer
Kishan, Amar U. , Steigler, Alison, Zapatero, A. , Guerrero, A., Joseph, David , Maldonado, Xavier , Wong, J.K. , Stish, Bradley J. , Dess, Robert T. , Pilar, Avinash , Wedde, Trude B. , Lilleby, Wolfgang , Fiano, Ryan , Stock, Richard G. , Demanes, D. Jeffrey, Martin, Santiago, Krauss, Daniel , Abu‐Isa, Eyad, Pisansky, Thomas M. , Choo, C. Richard, Greco, Stephen , Deville, Curtiland , McNutt, Todd , DeWeese, Theodore L. , Ross, Ashley E. , Ciezki, Jay P. , Karnes, R. Jeffrey , Tosoian, Jeffrey J. , Nickols, Nicholas G. , Bhat, Prashant , Shabsovich, David , Juarez, Jesus E. , Martin, Ting , Philipson, R., Chang, Albert J. , Kupelian, Patrick A. , Feng, Felix Y. , Reiter, Robert E. , Steinberg, Michael L. , Elashoff, David , Horwitz, Eric M. , Tendulkar, Rahul D. , Spratt, Daniel E. , Romero, Tahmineh , Davis, Brian J. , Deville, Curtiland , Spratt, Daniel E , Dess, Robert T , Ma, Ting Martin , Steigler, Allison , Denham, James William , Reddy, Chandana A. , Merrick, Gregory Stephen , Moran, Brian Joseph , Tran, Phuoc T , Martínez‐Monge, Rafael , Song, Daniel Y. , Tilki, Derya , Jiang, Tommy , Xiang, Michael H. , Rettig, Matthew B. , Berlin, Alejandro , Tward, Jonathan D. , Boutros, Paul C.

Mayo Clinic

JAMA Oncology | January 20, 2022 | Volume: 8 | Issue: 3 | Pages: e216871

10.1001/jamaoncol.2021.6871 | PMID 35050303 Get It